We propose to establish a Clinical-Epidemiology Center Consortium consisting of the collaboration of the following Institutions and their respective consortium partners: University of Michigan Medical Center- University of Michigan Cancer Center, Dartmouth Medical School- Norris Cotton Cancer Center, the Dana Farber Cancer Institute, Wellesley-St. Michael Hospital of Toronto, and the Henry Ford Medical System. We propose to pool our clinical experience to address the needs of the Early Detection Network by providing a large human subject pool for prevention clinical research, by devising innovative approaches to the validation of biomarkers, by sharing samples with Network laboratories and clinical centers, and by closely interacting with Network Biomarkers Development and Validation Laboratories. The following Specific Aims are proposed: l. Initiate validation studies for selected biomarkers for colorectal adenomas and cancers; 2. Refine statistical criteria for a clinical biomarker validation program, 3. Establish organizational structure for clinical studies of biomarkers for research in colon and other cancers, 4. Establish mechanisms for use of development funds; and 5. Describe quality assurance procedures.
Specific Aim #1 will be addressed through a four stage biomarker validation paradigm. The first stage consists of characterization studies to individual variability of a biomarker. The second stage consists of an intermediate size cross sectional validation trial. The third stage consists of a longitudinal observational trial. The fourth stage consists of a randomized, double blinded chemoprevention validation trial. In this application, we propose to validate five potential serum biomarkers and aberrant crypt foci as a pathologic biomarker.
Specific Aim #2 will be addressed through the development and prospective testing of newly developed statistical methods designed to assess biomarker efficacy in panels.
Specific Aim #3 will be addressed by establishing an Operations Center at the University of Michigan, a Data Management Unit at Dartmouth Medical School, and staffing all clinical sites with a dedicated clinical research associate experienced in sample collection, handling, tracking, shipment and data management.
Specific Aim #4 will be addressed through two proposed development projects, one assessing K-ras in stool guaiac samples and a second studying cytochrome P-450 isozymes in tissue samples. The a procedure for review of development projects is described.
Specific Aim #5 is addressed through description of data management, laboratory, pathology, and endoscopic quality control procedures. Our consortium, while focused upon the validation of biomarkers for colorectal cancer provides extensive, diverse human populations from which to validate early detection biomarkers for high priority cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA086400-02
Application #
6362770
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Project Start
2000-05-15
Project End
2005-02-28
Budget Start
2001-09-25
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$1,388,611
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Dig Dis Sci 63:1449-1453
Hannigan, Geoffrey D; Duhaime, Melissa B; Ruffin 4th, Mack T et al. (2018) Diagnostic Potential and Interactive Dynamics of the Colorectal Cancer Virome. MBio 9:
Rho, Jung-Hyun; Ladd, Jon J; Li, Christopher I et al. (2018) Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut 67:473-484
Poneros, John M; Faye, Adam S; Barr Fritcher, Emily G et al. (2017) A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus. Dig Dis Sci 62:1216-1222
Baxter, Nielson T; Ruffin 4th, Mack T; Rogers, Mary A M et al. (2016) Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med 8:37
Baxter, Nielson T; Koumpouras, Charles C; Rogers, Mary A M et al. (2016) DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Microbiome 4:59
Yu, Ming; O'Leary, Rachele M; Kaz, Andrew M et al. (2015) Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 24:1890-7
Zackular, Joseph P; Rogers, Mary A M; Ruffin 4th, Mack T et al. (2014) The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) 7:1112-21
Rho, Jung-hyun; Mead, Judson R; Wright, W Shea et al. (2014) Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics 96:291-9
Brenner, Dean E; Hawk, Ernest (2013) Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) 6:71-3

Showing the most recent 10 out of 32 publications